Abstract 2254
Background
5-year survival with platinum-based combination chemotherapies in testicular cancer is 95%. Existing prognostic scoring scales may be insufficient to predict which patient will benefit from treatment. Additional prognostic factors should be determined. Unlike left testicular vein, right testicular vein drains to vena cava. Therefore, the systemic spread of the testicular cancers of each side considered to be different due to the difference of vascular structures of the right and left testis. In this study, we aimed to investigate the effects of tumor localization on survival in patients with nonseminomatous testicular cancer.
Methods
We enrolled 321 non-seminomatous testicular cancer patients who followed up at Gulhane Research and Training Hospital in between January 1981, and December 2015. We retrospectively obtained data of demographic features, histopathological results, information of surgical operations and chemo-radiotherapy protocols, history of autologous stem cell transplantation from patients’ files.
Results
We enrolled 321 non-seminomatous testicular carcinoma patients and summarized demographic information and treatment methods in the table. Median age was 34 (18-77) years. The primary tumor was in left testis in 152 (47.2%) patients and in right testis in 170 (52.8%) patients. The most common histopathological diagnosis was mixed non-seminomatous germ cell tumor (39.4%). One hundred forty-six (44.3%) cases were metastatic at the time of diagnosis. Median follow-up period was 88.3 months (1-386). Median 10-year survival rate was 74.1%, and the 20-year survival rate was 70.7%. We examined the effect of primary tumor localization and found that primary tumor localization was significantly different regarding survival between left and right testis (337.6 months vs. NR, p = 0.001). In patients with a right testicular tumor the recurrence rate was significantly higher (84.7% vs. 68.2%; p = 0.002).
Conclusions
The localization of primary testicular tumor (left or right) was statistically significant regarding survival. The effect of tumor localization on survival was independent of the presence of metastasis at the time of diagnosis, histopathological type, site of metastasis, and disease stage.
Clinical trial identification
.
Editorial acknowledgement
Legal entity responsible for the study
Gulhane Education and Research Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3517 - Role of follow-up (FU) FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemotherapy and radiotherapy (RT), either concurrent (CRT) or sequential (ST).
Presenter: Bert Van Den Heuvel
Session: Poster Display session 3
Resources:
Abstract
5071 - Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Soohyeon Kwon
Session: Poster Display session 3
Resources:
Abstract
5306 - Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients.
Presenter: Maria Nieva
Session: Poster Display session 3
Resources:
Abstract
3407 - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma
Presenter: Shiqi Gong
Session: Poster Display session 3
Resources:
Abstract
3310 - Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
Presenter: Rachel Galot
Session: Poster Display session 3
Resources:
Abstract
2362 - Blood-based testing of mutations in patients with Head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
Presenter: Florentia Fostira
Session: Poster Display session 3
Resources:
Abstract
4533 - The head and neck Lung Immune Prognostic Index (HN-LIPI): a prognostic Score for Immune Checkpoint Inhibitors (ICI) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) patients.
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster Display session 3
Resources:
Abstract
5262 - Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
Presenter: Neus Baste Rotllan
Session: Poster Display session 3
Resources:
Abstract
3725 - Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy
Presenter: Jack Bui
Session: Poster Display session 3
Resources:
Abstract
2533 - A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Presenter: Luay Mousa
Session: Poster Display session 3
Resources:
Abstract